Skip to main content
Zymeworks Inc. logo

Zymeworks Inc. — Investor Relations & Filings

Ticker · ZYME ISIN · US98985Y1082 LEI · 894500AHOYAGYLYZJL67 US Manufacturing
Open in API
Filings indexed 306 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country US United States of America
Listing US ZYME

About Zymeworks Inc.

https://www.zymeworks.com/

Zymeworks Inc. is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company focuses on creating transformational therapies for patients with difficult-to-treat cancers and other serious diseases. Its product pipeline is driven by proprietary and clinically validated technology platforms for engineering next-generation antibody-drug conjugates (ADCs) and multispecific antibody therapeutics. Zymeworks operates as a royalty-driven organization with integrated in-house research and development capabilities, managing a portfolio of licensed healthcare assets while advancing its own novel therapeutic candidates.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-14 English
8-K - Zymeworks Inc. (0001937653) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 31, 2026, reporting the appointment of a new Executive Vice President and Chief Financial Officer. It details the new officer's background, compensation, and employment agreement. The key item is Item 5.02, which relates to the departure and appointment of directors or certain officers. There is no financial data or report content, only an announcement of management changes. Therefore, this filing fits the category of Board/Management Information (MANG). The document length is sufficient and contains detailed information about the management change, not a mere announcement of a report or certification. Hence, the classification is MANG with high confidence.
2026-04-01 English
8-K - ZYMEWORKS INC. (0001937653) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 2, 2026, which reports the entry into a material definitive agreement involving a sale agreement and a loan agreement related to royalty payments. The content focuses on the description of these agreements, their terms, and related financial obligations. There are no comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. The document is a current report disclosing a significant financing transaction and contractual arrangements, which aligns with updates on company fundraising or capital structure changes. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a simple press release, but a formal filing describing financing activity.
2026-03-02 English
10-K - ZYMEWORKS INC. (0001937653) (Filer)
Annual Report FY 2025
2026-03-02 English
8-K - ZYMEWORKS INC. (0001937653) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 2, 2026, by Zymeworks Inc. It announces the issuance of a press release with financial results for the three months and year ended December 31, 2025. The document itself is a current report that provides an update on recent events, specifically the release of earnings information, but does not contain the full financial statements or detailed analysis itself. The press release is attached as an exhibit, indicating this filing is primarily an announcement of financial results rather than the full earnings release document. Form 8-K filings with Item 2.02 (Results of Operations and Financial Condition) are typically classified as Earnings Releases (ER) because they announce quarterly or annual financial results highlights. The document length is 4800 characters, which is consistent with a brief announcement rather than a full report. Therefore, the appropriate classification is Earnings Release (ER).
2026-03-02 English
144 - Zymeworks Inc. (0001937653) (Subject)
Regulatory Filings
2026-02-14 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.